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a  b  s  t  r  a  c  t
Canonical  Hedgehog  (HH)  signaling  leads  to the regulation  of  the GLI  code:  the  sum  of  all  positive  and
negative  functions  of all GLI  proteins.  In humans,  the three  GLI  factors  encode  context-dependent  activ-
ities  with  GLI1  being  mostly  an  activator  and  GLI3  often  a repressor.  Modulation  of GLI  activity  occurs  at
multiple levels,  including  by  co-factors  and  by  direct  modiﬁcation  of GLI  structure.  Surprisingly,  the GLI
proteins,  and  thus  the  GLI  code,  is also  regulated  by multiple  inputs  beyond  HH signaling.  In normal  devel-
opment  and  homeostasis  these  include  a multitude  of  signaling  pathways  that  regulate  proto-oncogenes,
which  boost  positive  GLI function,  as  well  as  tumor  suppressors,  which  restrict  positive  GLI activity.  In
cancer,  the  acquisition  of  oncogenic  mutations  and  the  loss  of  tumor  suppressors  – the  oncogenic  load
–  regulates  the  GLI  code  toward  progressively  more  activating  states.  The  ﬁne  and  reversible  balance  of
A R Ancogenes
tem cells
GLI activating  GLI and  GLI  repressing  GLI states  is  lost  in cancer.  Here,  the  acquisition  of  GLI levels
above  a  given  threshold  is  predicted  to lead  to advanced  malignant  stages.  In  this  review  we  highlight
the  concepts  of  the  GLI code,  the  oncogenic  load,  the  context-dependency  of GLI  action,  and  different
modes  of  signaling  integration  such  as  that  of  HH  and  EGF.  Targeting  the  GLI  code  directly  or  indirectly
promises  therapeutic  beneﬁts  beyond  the  direct blockade  of individual  pathways.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Model for the GLI code and its morphogenetic activity leading to the creation
of context-dependent diversity. A gradient of HH  ligands is interpreted, canonically,
by  a combinatorial and context-speciﬁc distribution of repressor and activator activ-
ities of the three GLI proteins, the GLI code. Note that GLI1 and GLI2 have strong
activating action and GLI3 is a strong repressor in many contexts. Combinatorial GLI
activities are then modiﬁed by positive or negative modiﬁers leading to differen-
tial regulation of target genes, which may either respond to create graded levels of
expression of speciﬁc genes or induce speciﬁc genes in given thresholds. The output4 F. Aberger, A. Ruiz i Altaba / Seminars in C
. Introduction
The molecular dissection of the Hedgehog (Hh)-Gli signal trans-
uction pathway in insects (e.g. [1–7]) and vertebrates (e.g. [8–16]),
as revealed it to be complex and context-dependent with a sur-
rising number of distinct cellular outputs.
Complexity is found at every level of signaling, from multiple
igands with apparently different strengths, and perhaps differ-
nt properties, multiple membrane components (e.g., PTCH1 vs.
TCH2), a bagful of intracellular regulators and the existence of
hree GLI proteins in humans that mediate ﬁnal genomic responses,
o ligand-driven pathway activation. Complexity is also found in
he tissue – speciﬁc expression of different modulators and in the
ultiple variations of the canonical pathway found in different
pecies.
We are just beginning to understand the meaning of species-
peciﬁc differences in Hh signaling but what is clear is that a
ingle-species (e.g., mouse)-centric view is not universally infor-
ative. How or why organisms would have evolved multiple Ptc
eceptors (as in worms) for instance, increase the number of Hh lig-
nds or of Gli proteins (as in zebraﬁsh), or constraint HH signaling
o primary clia in some species and tissues is unclear but likely to
ave important clues to speciation and the evolution of the mor-
hogenetic plan (reviewed in [15]).
The outputs are numerous since the HH pathway controls
spects of cell proliferation, survival, migration and stemness. How
hese are orchestrated over time in developing tissues remains
nclear. The GLI proteins also regulate and are regulated by tumor
uppressors, such as p53 and this reveals yet another impor-
ant aspect of HH-GLI signaling: its major role in human cancer
reviewed in [16]).
But perhaps the most intriguing aspect of this and other
athways is their context-dependency. How is it that the same
xtracellular input can be interpreted differently by responding
ells? How is it that reception of a HH ligand can lead to diverse
esponses in time, space and in different cell types? While the com-
lexity of the pathway makes a complete discussion for a review
hapter not feasible, we focus here on the GLI zinc ﬁnger transcrip-
ion factors, which represent the terminal station of the canonical
H signaling path. Whereas other reviews and papers address key
spects of the morphogenetic function of HH ligands (e.g. [17–20])
e elect to focus this review on 3 key points of the highly context-
ependent nature of the HH-GLI pathway, where the history and
he molecular make-up of the receiving cell determines the qual-
tative and quantitative output and biological effect: 1 – The GLI
ode; 2 – Regulation of the GLI code by non-HH signals and by the
ncogenic load; and 3 – Mechanisms of GLI regulation. In choosing
o do so, here we wish to emphasize the fact that the GLI tran-
cription factors act as key determinants in the interpretation of
ontext- and concentration-dependent canonical HH-GLI signaling
n development and disease, and that the GLI code is a signaling
ntegration node.
. The GLI code
The GLI code model [21,22] considers the total GLI function as a
alance of positive activator (GLIA) and negative repressive (GLIR)
ctivities with GLI1 being mostly a positive transcription factor and
LI3 mostly a transcriptional repressor. The GLIA:GLIR ratio is thus
ritical, being highly regulated, species- and context-speciﬁc, and
ighly dynamic (Fig. 1).GLI proteins belong to the superfamily of zinc ﬁnger transcrip-
ion factors with ﬁve sequential zinc ﬁngers of the C2H2 type
onstituting the sequence speciﬁc DNA binding domain. GLI1 (orig-
nally GLI) was ﬁrst identiﬁed as an ampliﬁed gene in a humanof  these genetic changes is then the creation of spatially and/or temporally distinct
outputs and behaviors.
glioblastoma cell line [23,24]. Later on and independently, what
turned out to be its ﬂy homolog, Cubitus interruptus (Ci) was
identiﬁed and placed in the Hh pathway [7,25–27]. GLI1 was  not
linked to the vertebrate Hh pathway until later [12,28]. While the
Drosophila genome encodes only one GLI protein, the mouse and
human genomes comprise three: GLI1, GLI2 and GLI3.
One of the most remarkable features of GLI proteins is that in
canonical HH signaling they can act as both transcriptional acti-
vators and repressors [29–33]. The situation is likely to be complex
as all GLI proteins can act as activators or repressors in a stage-
dependent and target gene-dependent manner [34]. However, the
basic idea of the GLI code is useful as a framework and generally
considers GLI1 as an activator and GLI3 mostly as a repressor.
In the absence of HH pathway activity positive GLI function is off,
GLI1 is not transcribed [12] and the GLI code is tipped toward a GLIR
output, thus leading to pathway silencing. In this context, GLI2/3
proteins are proteolytically processed into C-terminally truncated
repressors consisting of an N-terminal repressor domain and the
DNA binding zinc ﬁngers, but lacking the C-terminal transactivation
domain. There is also evidence for GLI1 isoforms but how these are
produced is not clear [35].
GLI processing in the absence of HH signaling is triggered by
sequential phosphorylation of Ci or GLI2/3 by Protein Kinase A
(PKA), Glycogen Synthase Kinase 3-beta (GSK3)  and Casein Kinase
1 (CK1) [36] followed by proteasomal degradation of the C-terminal
region [31,33]. Truncated Ci/GLI repressor binds to GLI sites in HH
target promoters, thereby shutting off target gene expression (e.g.
[37–39] (reviewed in [16,40])).
Activation of canonical HH signaling abrogates GLI processing
allowing full-length and active GLI (GLIA) to enter the nucleus
and turn on target gene expression. HH-GLI signaling also has
feed-forward and feedback loops. In the latter case, GLI1 directly
regulates PATCHED1 (PTCH1), genetically a SMOOTHENED (SMOH)
ell & Developmental Biology 33 (2014) 93–104 95
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trolled levels of GLIA/GLIR. The balance can be tipped one way or another, thus
allowing for the highly controlled ON-OFF switch. For simplicity, feed-forward and
feedback regulatory loops are not included. (B) In cancer, the loss of tumor sup-
pressors and the presence of mutant oncogenes lead to the massive deregulation ofF. Aberger, A. Ruiz i Altaba / Seminars in C
nhibitor, but it also autoregulates itself. GLI2/3A activity leads to
LI1 expression, which further positively boosts GLI1 transcription.
ow his apparently close loop is broken is unclear, in order to allow
recise and reversible control of the GLI code, which is of utmost
mportance for proper development and health. It is also unclear
ow the GLI proteins act since there is evidence that the GLI code
ill be highly reﬁned and meticulously regulated given that GLI1,
LI2 and GLI3 can act in a combinatorial manner [30,34,41–43].
The importance of the critical and tight regulation of the GLI
ode is illustrated on the one hand by the fact that varying lev-
ls of HH-GLI will induce different numbers of neural stem cells in
ormal development and homeostasis [35,44–48], and also induce
ifferent cell fates in the ventral neural tube in response to a mor-
hogenetic gradient of HH ligands [8,9,11,49–51]. On the other
and, genetic and/or epigenetic changes leading to irreversible
ctivation of GLIA, and GLI1 [52], can drive a variety of malignant
tates ranging from cancers of the brain, skin, breast, prostate and
igestive tract to malignancies of the hematopoietic system (e.g.
16,52–60]).
. Regulation of the GLI code by non-HH signals and by the
ncogenic load
The GLI code may  be seen as the essential parameter to regu-
ate canonical HH output. Its regulation ﬁrst appeared to be strictly
ependent on the presence of speciﬁc levels of HH ligands. Indeed,
LI1 transcription is so far the only general biomarker of a cell’s
esponse to HH ligands [12], it can be a diagnostic tool for HH path-
ay activity [52] and is used to measure the efﬁciency of SMOH
lockers in clinical samples [61–63].
However, surprising data revealed that the GLI1 code and
ctivity can also be modulated by non-HH signals [64,65]. Such
egulation occurs in normal and in disease contexts and here we
ighlight key examples (Fig. 2).
.1. Tumor suppressors negatively regulate GLI1 activity in
ormal development and homeostasis.
The ﬁrst example of tumor suppressors regulating normal GLI
ctivity came from the work on p53, where p53 negatively regu-
ates GLI1 [35]. Interestingly, GLI1 also regulates p53 [35,66], thus
reating a regulatory loop in which the GLI code is subjected to
he precise regulation by p53. Modulation of p53 by GLI1 takes
lace through MDM  factors [35,66] and it remains unclear how p53
epresses GLI1 although it involves okadaic acid-sensitive protein
hosphatases, possibly PP2A [35].
.2. Loss of tumor suppressors leads to unregulated GLI1 activity.
Loss of p53 is a common occurrence in human tumors and this
rovokes the unregulated up-modulation of GLI1, thus leading to
ncreased tumor cell proliferation and increased self-renewal of
ancer stem cells [35]. Similarly, PTEN negatively regulates GLI1
ctivity in different human tumors that include melanomas [65].
his activity may  ﬂow through the action of AKT, which positively
egulates GLI1 (see below) and is itself negatively modulated by
TEN [65,67], a repressor of AKT (see below). Many other tumor
uppressors have since been found to regulate GLI. For example,
oss of the SNF5 or Menin leads to activation of GLI1 [68,69].
.3. Oncogenes, and the pathways that normally regulate
roto-oncogenes, positively regulate GLI1.
Not only do common tumor suppressors repress GLI1 but com-
on  oncogenes, including RAS, MEK, MYC  and AKT, positivelythe  GLI code and to a constitutively active ON state (GLIA). Note that given the sta-
ble genetic changes resulting from gene mutation, the GLI code is no longer under
homeostatic control.
regulate GLI1 in different tumor types [65,70]. Moreover, regulation
of cMYC [71,72] and possibly of AKT [73] by GLI1, may  establish pos-
itive feed-forward loops. Together, this insures that GLI1 activity
will increase as tumor suppressors are lost and oncogenes gained.
This has led to the idea that it is the stepwise gain of oncogenic
events and loss of tumor suppressors – named the oncogenic load
– that leads to the acquisition of higher and higher GLI1 levels
and thus higher and higher levels of GLIA [64]. These increases
then drive GLIA beyond thresholds that induce changes in cell
fate and behavior, such as the acquisition of metastatic behavior
[64,70,71,74].
Note that one key contribution to the oncogenic load in a num-
ber of cancers, such as basal cell carcinomas, is the oncogenic
mutation of the HH-GLI pathway itself, often through loss of PTCH1
in familial tumors [75,76], or loss of PTCH1, gain of SMOH activity or
increase of SHH levels in sporadic cancers [52,53,56,65,70,77–86].
Interestingly, initial evidence for non-HH signaling regulating
the GLI code came from studies with frog embryos where GLI2
96 F. Aberger, A. Ruiz i Altaba / Seminars in Cell & Developmental Biology 33 (2014) 93–104
GLI1p53 NANOG
AKT
mTOR
MEK
Survival
Stemness
Migration
MetabolismProliferation
RAS
PTEN
Peptide growth factors
Receptors
Intracellular
transduction
Modifiers
ZIC, CBP, etc 
Nuclear node
Cellular fates 
and behaviors
GLI code
Context-dependent 
signal integration
Context-dependent 
output
Context-dependent 
regulation
FGF EGFHH
SMOH
FGFREGFR
TGFβ
PTCH
Fig. 3. A working framework for the GLI code as a node for signal integration. Multiple signaling inputs from diverse pathways, including but not restricted to HH, EGF, FGF,
TGF,  can converge on GLI regulation, changing the GLI code. Integration can also take place above, through crosstalk (gray arrows). The position of the different components
is  not related to each other but shown as examples of the types of components involved in the signaling cascades. The GLI code, a transcriptional regulatory node, is then
modulated by additional context-dependent inputs (arrow and T bar, such as ZIC proteins) that include a negative feedback loop with p53 [35] and a positive feed-forward
regulatory loop with NANOG [133]. The outcome, through differential regulation of target genes, is context-dependent and includes change in stemness, survival, proliferation
migration and metabolic regulation. This framework can help not only to conceptualize cell behavior resulting from multiple signaling events but also design multi-target
t s dive
w
[
w
s
e
G
o
b
G
o
t
s
G
o
t
[herapies to increase efﬁciency and prevent resistance. Note that each input also ha
as found to act in the FGF-Brachyury loop in the early mesoderm
87]. In a separate study, the growth of mouse brain neurospheres
as found to be dependent on both EGF and Sonic HH (SHH)
ignaling but only after decreasing their levels [46,47]. This syn-
rgism between EGF and SHH [47], together with the regulation of
LI2 by FGF [87], and the regulation of GLI1 by RAS-MEK-AKT [65]
pened a new chapter on the regulation of the GLI code, in this case
y non-HH signals. These studies predicted the modulation of the
LI code and of GLI1 by peptide growth factors acting upstream
f RAS, MEK  and AKT such as FGF, EGF, and many other ligands
hat trigger receptor tyrosine kinases and activate RAS and down-
tream events. These ﬁndings can therefore help to explain why  the
LI code and GLI1 in particular, as the ﬁnal positive feed-forward
utput, is important in human cancer. The GLI code, and GLI1, act at
he tip of a funnel to integrate multiple outputs. Such a funnel idea
22] (Fig. 3) has strong implications for understanding the logic ofrgent pathways not shown in the scheme.
signaling but also places the GLI code, and GLI1 in particular, in the
line of ﬁre for the development of novel therapies against cancer.
Additional work has shown that oncogenic RAS can regulate
GLI1 in the apparent absence of Smo  in pancreatic cancer in mice
[88] being required for RAS-mediated tumorigenesis [89], and that
EGF signaling cannot only synergize with HH-GLI outputs but also
modify its outputs [90–93]. Many other proto-oncogenic and onco-
genic inputs have since been shown to regulate the GLI  code in
different contexts, such as for instance the EWS/FLI1 fusion onco-
protein [94,95], TGF signaling [96,97], the mTOR/S6K1 axis [98],
WNT signaling [99] (although WNT  genes can also be targets and
mediators of GLI function [100,101]) and WIP1 [102].Finally, interactions between pathways may be balanced by
direct transcription factor binding such as that between GLI  repres-
sors and SMAD proteins, the latter being the mediators of normal
and oncogenic BMP  and TGF signaling [103,104].
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.4. HH and EGF in human basal cell carcinoma
The integration of HH and EGF signaling [46,47,92] has been
ntensely studied given its developmental interest and its high ther-
peutic relevance. Here we describe HH-GLI and EGF crosstalk as
ne example of how a cell can integrate apparently parallel signal
nputs.
HH and EGF signaling synergistically promote oncogenic trans-
ormation and integration of the signals can occur at different
evels. SHH can transactivate the EGF receptor (EGFR) [105]. In
ddition, EGF activates the RAS-MEK cascade and this can super-
ctivate GLI1 [65]. Moreover, both pathways can converge on the
evel of common target gene promoters resulting in selective and
ynergistic modulation of gene expression (reviewed in [59,106]).
Global gene expression studies of human keratinocytes with
ombined or single activation of HH-GLI and EGFR revealed three
lasses of target gene responses: (i) genes responding to HH-GLI
nly, (ii) genes activated or repressed by EGFR only and (iii) genes
nly or at least preferentially responding to combined and simul-
aneous activation of both pathways [92]. Notably, class III genes,
lso referred to as HH-EGFR target genes or cooperation response
enes, contain functional GLI binding sites in their promoters, sug-
esting that signal integration occurs at the level of HH-EGFR target
ene promoters [92]. It is important to note that signal cooperation
s a selective process as classical HH-GLI target genes such as PTCH1
r HHIP are not affected by parallel EGF signaling in keratinocytes
90,92,93].
In this context, cooperation of EGFR with GLI1 and GLI2 depends
n activation of MEK/ERK signaling while PI3K/AKT function is
ispensable downstream of EGFR. MEK/ERK induced phosphory-
ation and activation of the JUN/AP1 transcription factor is the
ritical event at the terminal end of the EGFR cascade, inducing
inding of activated JUN and GLI to common HH-EGFR target pro-
oters, thereby cooperatively regulating target gene expression
nd transformation [92,93]. It is noteworthy that although basi-
ally all receptor tyrosine (RTK) pathways (e.g., HGF, VEGF or FGF)
ctivate MEK/ERK, this is context-dependent as not all of them syn-
rgize with HH-GLI in human keratinocytes, possibly because they
ail to activate JUN/AP1 in these cells [90]. So far, only EGFR and
DGFRA [107] signaling have been identiﬁed as being able to stim-
late both MEK/ERK and JUN/AP1 and synergize with HH-GLI in
asal cell carcinoma (BCC) (Fig. 4). Importantly, the beneﬁcial effect
f EGFR blockade in HH-driven BCC and pancreatic cancer mod-
ls can be synergistically improved by combined targeting of both
athways [90,93,108].
.5. HH-GLI and WNT-TCF in human colon cancer
A second example involves the interaction between HH and
NT  signaling in human colon cancer [71]. In this context,
nhanced GLl1 represses WNT-TCF targets and repression of WNT-
CF targets via dominant-negative dnTCF leads to enhanced HH-GLI
argets [71]. This mutually inhibitory interaction is distinct from
hat seen in other contexts between these two pathways (e.g.
100,109]) and is relevant in the context of the metastatic tran-
ition of human colon cancers. Patients with metastases, but not
hose without, harbor local intestinal tumors that display repressed
NT-TCF and enhanced HH-GLI pathways as assessed by target
ene signatures [71]. This switch, from high WNT-TCF, which drives
nitial intestinal tumorigenesis (e.g. [110]), to low WNT-TCF and
nhanced HH-GLI in advanced and metastatic tumors was totally
nexpected and is critical as experimental repression of WNT-TCF
r enhancement of HH-GLI in xenografts leads to increased metas-
ases in mice [70,71]. Blocking WNT-TCF in advanced cancers is
hus not recommended.evelopmental Biology 33 (2014) 93–104 97
The interaction between the HH-GLI and WNT-TCF path-
ways is complex and stage-dependent: TCF activity, essential for
CATENIN activation of WNT-TCF targets, is required for intestinal
initiation and for adenomas. (e.g. [111]). However, while it is also
required for advanced human colon cancer cells in vitro [110] it is
not required in vivo [71]. Moreover, HH-GLI is dominant: enhanced
GLI1 levels, or suppression of PTCH1, rescue the deleterious effects
of TCF blockade by dnTCF [71]. There thus appears to be a functional
cross-pathway switch at the metastatic transition. WNT-TCF may
keep tumors in a crypt-like state and enhanced HH-GLI together
with repressed WNT-TCF may  allow tumors to change fate and
behavior and become metastatic [71].
Modeling such interactions in mice has revealed that Hh-Gli
signaling is a parallel requirement since intestinal tumorigenesis
can be initiated by loss of Apc but it is fully rescued by concomitant
loss of Smo  in the intestine [112,113].
Understanding how WNT-TCF and HH-GLI inputs are inte-
grated is of great importance given the essential functions of both
pathways in stem cells, human disease and development. Such inte-
gration of parallel signaling inputs can take place at multiple levels.
In the case of WNT-TCF signaling, there is evidence for binding of
CATENIN, the ﬁnal output of canonical WNT  pathway and both
GLI3 C′-terminally deleted repressors and GLI1 [71,114]. Whether
this interaction is the key mode of integration remains to be deter-
mined.
4. Mechanisms of GLI regulation
4.1. Context-dependent regulation of GLI activity by modulation
of DNA binding
GLI proteins regulate target gene promoters by binding the
consensus sequence GACCACCCA [115,116]. The two  cytosines
ﬂanking the central adenine in the consensus sequence are essen-
tial for binding, while the other positions allow a certain degree
of variation (Fig. 5A) [117,118]. Sequence-speciﬁc DNA binding to
the cis-regulatory region of a GLI target gene mainly involves zinc
ﬁngers 4 and 5 which make extensive base contacts within the
9-mer binding sequence, while ﬁngers 2–3 mainly establish a few
contacts with the phosphate backbone. Extensive protein–protein
contacts between ﬁngers 1 and 2 apparently contribute to the
overall stability of the DNA binding domain [119] (Fig. 5B). Fingers
1 and 2 also provide protein–protein interaction sites to form GLI2,
GLI3 and ZIC2 complexes [34].
Although global chromatin immunoprecipitation analyses and
in vitro GLI-DNA binding screenings conﬁrmed the consensus
sequence as dominant binding site for GLIs [38,39,115,116,120],
the importance of GLI binding sequences with 1–2 base pair
substitutions is underappreciated and therefore possibly neglected
or overseen in many studies. Variations of the consensus sequence
while preserving functionality contribute to subtle differences in
DNA–protein binding afﬁnity and hence may  have a signiﬁcant
impact on the transcriptional output in response to deﬁned GLI
activator levels [117,118,121]. For instance, substitution of the con-
sensus cytosine at position 7 for adenine results in a GLI binding
site with even enhanced transcriptional response compared to the
consensus motif [117].
Variants of the consensus GLI binding site contribute also to
selective target gene activation by different GLI proteins. Although
all GLI proteins bind the 9-mer consensus sequence with compa-
rable afﬁnity, repressor and activator forms bind the same sites
[37], and different GLI proteins affect the same target genes differ-
ently [34,41]. For example, GLI2 induces expression of the direct
GLI target BCL2 signiﬁcantly more strongly than GLI1 and system-
atic analysis of the BCL2 promoter reveals that one of the three
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Fig. 4. Modes of HH-EGF signaling integration. (A) Canonical HH-GLI signaling activated by binding of SHH to its receptor PTCH results in ciliary localization of SMOH and
subsequent GLI activation (GLIA). HH-GLI signaling alone only activates classical GLI targets including HHIP and GLI1 but fails to induce HH-EGFR cooperation target genes.
(B)  Concomitant activation of HH-GLI and EGF/PDGF signaling (EGFR or PDGFRA) can lead to synergistic interactions [46,47]. Such interactions can result in (i) cross talk
between SHH and EGFR in neural stem cells [105], (ii) enhancement of GLI1 activity by RAS/MEK signaling in melanomas and other tumor cells [65], and/or (iii) synergistic
promotion of basal cell carcinoma and pancreatic cancer by selective activation of HH-EGFR target genes such as CXCR4, FGF19, SOX9 and TGFA [90,92,93]. In the latter
case,  integration of HH-EGFR signaling occurs at the level of common target gene promoters. Activation of EGF signaling induces the RAS/RAF/MEK/ERK cascade eventually
leading to activation of GLI1 or/and of the JUN/AP1 transcription factor. JUN synergizes with GLI activator forms by co-occupying selected target gene promoters leading to
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alidated GLI binding sites accounts for the preferential response
o GLI2 [122].
In line with the documented morphogenetic activity of HH-GLI
ignaling e.g., in the neural tube (reviewed in [123,124] variations
n binding site afﬁnity are likely to play a major role in the inter-
retation of threshold GLI activity levels above which a gene is
ranscribed or below which the very same gene remains silent.
ccordingly, high afﬁnity GLI binding sites in the cis-regulatory
egion of GLI targets will ensure expression at both high and low
evels of GLI activator activity, while targets with low afﬁnity bind-
ng sites will respond to high GLI activity only, as demonstrated
or the response of neural tube patterning genes controlled by GLI
118]. High afﬁnity binding may  be generated by GLI binding site
equence variants and/or multiple repeats of the binding motif. This
lso suggests that not only quantitative differences in the abso-
ute GLIA protein level or activity determine the context-dependent
ellular responses to HH-GLI [50,51,125] but also differential epi-
enetic modiﬁcations of the cis-regulatory regions of GLI targets
ffecting GLI-DNA binding afﬁnity. Cell-type speciﬁc histone acety-
ations or methylations and/or CpG methylation patterns of GLI
arget gene promoters are thus likely to modulate both the qualita-
ive and quantitative response to GLI [118], an area in the HH-GLI
eld that has not yet been explored in great detail.Distinct combinatorial GLI function could also account for the
ubstantial difference and context-dependency of GLI1 regulated
ene networks in the early embryo [30,34,41], as well as in the
ormal developing cerebellum and in medulloblastoma [120]. A.g., BCC and pancreatic cancer).
genome-wide survey of GLI1 binding locations revealed numerous
GLI1 binding sites in both the normal and malignant tissues, though
the location and expression pattern diverged signiﬁcantly between
normal and malignant cells [120].
Although global ChIP approaches successfully and reliably iden-
tiﬁed classical HH-targets in addition to novel targets, it should be
noted that these studies were performed with epitope tagged and
overexpressed GLI [38,39,118,120], which may  fully mimic endoge-
nous GLI function. It is therefore possible that future approaches
will reﬁne our current understanding of context-dependent target
gene regulation, once reliable and high-quality antibodies suitable
for the isolation of rare endogenous GLI proteins bound to DNA
become available.
4.2. Context-speciﬁcity of the GLI code by interactions with
co-factors
Speciﬁcity and activity of transcription factors (TF) heavily
depend on interactions with activating or repressing co-factors as
well as on co-occurrence of other TF that can bind and/or act coop-
eratively to regulate target gene expression (Fig. 5C). It follows that
the absence or presence of GLI co-factors or cooperative transcrip-
tion factors within a given cellular context is a major determinant
of the transcriptional output.
An example of such an interplay with cofactors that regulates
the GLI code is the functional interaction between Zic and Gli pro-
teins [126] (Fig. 3). The Zic factors are nuclear proteins with a
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Fig. 5. GLI DNA binding and context-dependent target gene regulation. (A) Consensus 9-mer GLI DNA binding motif calculated from experimentally validated GLI binding
sites.  The motif was generated with a set of 22 experimentally validated GLI binding sites using WebLogo3 [168]. Positions 4C and 6C are essential for DNA binding while
basically all other positions allow a certain degree of sequence variation resulting in distinct target gene activation efﬁciencies. (B) 3D model of the GLI  DNA binding domain
composed of ﬁve zinc ﬁngers and its interaction with the consensus binding sequence. Note that ﬁngers 4 and 5 form extensive base contacts thereby determining binding
speciﬁcity (source: Protein Databank ID 2GLI; [119]). (C) Non-exhaustive models of context-dependent target gene activation. Here, GLI activator (GLIA) and GLI repressor
forms (GLIR) binding the same target sequences refer to the GLI code. (i) Classical target gene activation model with GLIA binding to the promoters of canonical targets such as
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argets.  (iv) Context-dependent combinatorial binding of GLIA and cooperating tra
ynergistic modulation of gene expression.
LI-type 5 zinc ﬁnger domain [127] that can recognize GLI bind-
ng sites albeit with different afﬁnities [128]. They modify GLI
utputs [126,128] and can interact through the ﬁrst two zinc ﬁngers
34,129]. In the early neural plate of frog embryos, Zic2 is expressed
n speciﬁc longitudinal bands that are adjacent to zones of pri-
ary neurogenesis, which is triggered by GLI proteins expressed
hroughout the plate. The overlap leads to the repression of Gli
roneurogenic function by Zic2 in restricted domains, thus leading
o the deﬁnition of domains of neurogenic differentiation [126].
n this context, Zic2 mimics C-terminally truncated Gli repressors
126]. In a different context Zic2 may  mimic  positive GLI function
s it is required for ventral forebrain fates: Loss of ZIC2 is associatedi) of GLIR with co-repressors (CoR) modiﬁes the GLI code and expression of HH-GLI
tion factors (TF) (e.g., JUN, SOX2) to common target promoters can also result in
with human holoprosencephaly [130], paralleling the association
of this malformation with loss of SHH [131] or GLI2 [132].
A second case that exempliﬁes a different form of interaction
is the cross-functional network of GLI1, p53 and NANOG (made
from NANOG1 and NANOGP8 in human cancer cells) (Fig. 3). As
discussed above p53 negatively regulates GLI1 [35] and GLI1 neg-
atively regulates p53 [35,66]. p53 would appear to be active in
most cells. However, a further layer of regulation is provided by the
homeodomain and stemness factor NANOG, which forms a positive
feed-forward loop with GLI1 [133]. Interestingly, this loop is also
regulated negatively by p53, establishing a highly dynamic node
that will be affected by any input that will affect GLI1, NANOG
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nd/or p53 [133] (Fig. 3). Regulatory mechanisms involve regula-
ion of MDM  proteins by GLI1, protein phosphatase action, direct
LI regulation of NANOG1 expression and the action of microR-
As [35,66,134,135]. Thus, in adult cells expressing NANOG, likely
tem cells and cancer stem cells, the GLI code will be modulated
y additional positive mechanisms. As p53 is often lost in cancer,
his is predicted to free the GLI1-NANOG loop from negative regu-
ation, allowing unrestricted activity of GLIA. The essential role of
ANOG and HH-GLI is demonstrated by their regulation of clono-
enic gliomaspheres and by their absolute requirement for the
rowth of primary human glioblastomas orthotopically engrafted
n the brains of host mice [133].
Additional mechanisms of GLI code regulation include inter-
ctions with CREB-binding protein (CBP). Genetic and functional
tudies ﬁrst carried out in the fruit ﬂy and later in mammalian cells
ave identiﬁed CBP as essential co-factor for Ci and GLI3 mediated
arget gene activation [136]. Haploinsufﬁciency of CBP is associated
ith Rubinstein-Taybi syndrome, a genetic disorder character-
zed by several developmental anomalies with partially striking
imilarities to defects observed in patients suffering from Greig’s
ephalopolysyndactyly syndrome, which is caused by mutations in
he GLI3 gene [136–139]. Given the intrinsic histone acetyl trans-
erase (HAT) of CBP/p300 [140], CBP-GLI interactions are likely to
ause epigenetic changes of the cis-regulatory region of GLI targets
aking them more accessible to other transcriptional regulators. In
ine with this hypothesis, histone acetyl transferase PCAF interacts
ith GLI1 and enhances HH-GLI target gene expression in medul-
oblastoma cells by promoting the level of H3K lysine modiﬁcations
141]. However, when functioning as ubiquitin ligase, PCAF can also
egatively regulate GLI activity under genotoxic stress conditions
142].
Further evidence for epigenetic modiﬁcations in context-
ependent GLI activity comes from studies of SAP18, a component
f the histone deacetylase complex. Recruitment of SAP18 to GLI via
inding to the negative GLI regulator Suppressor of Fused (SUFU)
143] is crucial for efﬁcient repression of GLI target genes [144,145].
ike SAP18, Atrophin (Atro) has been identiﬁed in ﬁsh and ﬂies as a
LI/Ci cofactor required for target gene repression via recruitment
f histone deacetylases [146].
TBP-associated factor 9 (TAF9) encodes a transcriptional co-
ctivator that directly interacts with the GLI activator forms GLI1
nd GLI2 via their transcriptional activation domain [147]. TAF9 has
een shown to enhance the transcriptional activity of GLI, which
ay  play an oncogenic role in lung cancer. Both genetic and chem-
cal inhibition of TAF9-GLI interactions dampen GLI target gene
ranscription, thus providing a possible therapeutic strategy to tar-
et oncogenic HH-GLI signaling downstream of the common HH
rug target SMOH [147].
Furthermore, direct interaction of GLI3 with MED12, a subunit
f the RNA Polymerase II transcriptional Mediator, enhances the
ranscriptional response to GLI activator by reversing the Mediator-
egulated repression of HH target genes [148].
Transcriptional activity of GLI proteins can be negatively reg-
lated by binding to cofactors including 14-3-3 protein. Notably,
KA phosphorylation at amino acid residues distinct from those
nhancing GLI repressor formation promote association of 14-3-3
ith GLI2 and GLI3, thereby repressing their transcriptional activity
ndependent of the intrinsic N-terminal repressor domain of GLI2
nd GLI3 [149].
Studies addressing selected GLI target gene promoters together
ith global approaches analyzing the entire landscape of GLI tar-
et gene promoters revealed the importance of combinatorial
ranscription factor binding in context-dependent HH-GLI target
ene regulation (Fig. 5C). For instance, high level activation of
 subgroup of direct GLI target genes such as IL1R2, JUN/AP1,
r ARC was abolished by inhibition of JUN expression as fullevelopmental Biology 33 (2014) 93–104
transcriptional activation of these targets is likely to require co-
occupancy of their promoter region by GLI and JUN/AP1, similar
to the mechanism accounting for HH and EGF signal integration
[90,93,150].
Another example of how combinatorial binding of transcription
factors controls context-dependent HH output is illustrated by the
ﬁnding that co-occupancy of selected GLI targets by GLI1 and SOX2
is required for full activation of a neural gene expression signature
[118].
Motif enrichment analyses identiﬁed E-box sequences as fre-
quently co-occurring with GLI binding sites in GLI target genes
expressed in medulloblastoma [120]. It is therefore possible, that
E-box binding bHLH transcription factors cooperate with GLI in the
control of tissue speciﬁc target gene expression and cancer devel-
opment, a model that still needs to be conﬁrmed in future studies.
4.3. Modulation of GLI DNA binding afﬁnity and transcriptional
activity by post-translational modiﬁcations
Fine-tuning and reversible activation/termination of HH-GLI
signaling is critical to proper development and health. As outlined
in the introduction of this article, numerous reports have provided
a wealth of data showing that precise control of HH-GLI signal
strength occurs at nearly every level of the canonical HH  cascade,
ranging from the control of ligand production and ligand-receptor
interactions down to the numerous molecular interactions and
modiﬁcations of GLI proteins eventually determining the molecular
phenotype by controlling gene expression in response to pathway
activity [20,22,40,54,151].
At the level of GLI code, a number of post-translational mod-
iﬁcations of GLI proteins play a fundamental role in its control
by affecting GLI stability, subcellular localization and DNA binding
ability [152–155] (reviewed in [20,40]). To remain focused on the
topic of context-dependent GLI activity, we  concentrate here on GLI
modiﬁcations that directly affect the intrinsic GLI transcriptional
activity.
Post-translational modiﬁcations of GLI proteins result in drastic
modiﬁcations of activity. For instance, phosphorylation and acety-
lation of GLI1/2 at speciﬁc amino acid residues have a major impact
on the ability of GLI proteins to regulate target genes by modifying
their binding to target promoters (see Fig. 6) [156–158].
Atypical Protein Kinase C/ (aPKC) has been identiﬁed as both
a HH-GLI target gene and major regulator of GLI activity in basal
cell carcinoma. aPKC acts downstream of the essential HH effec-
tor and drug target SMOH by phosphorylating GLI1 at amino acid
residues located in the zinc ﬁnger DNA binding domain. GLI1 phos-
phorylated by aPKC displays enhanced DNA binding and maximum
transcriptional activity. Of note, hyperactivation of aPKC in BCC can
account for SMOH inhibitor resistance, rendering it a promising
drug target for the treatment of cancer patients unresponsive to
classical HH pathway inhibitors targeting SMOH [156]. aPKC (also
referred to as PRKCI) can affect HH-GLI signaling also by phospho-
rylating the transcription factor SOX2. Phospho-SOX2 acts a potent
transcriptional activator of HH acetyltransferase expression, lead-
ing to increased HH ligand production and cell-autonomous HH-GLI
activation in lung squamous cell carcinoma [159].
In addition to aPKC phosphorylation of GLI1, several serine and
threonine residues in the N-terminal region of GLI1/2 serve as phos-
phorylation sites involved in GLI activation. In esophageal cancer
cells, activation of mTOR/S6K1 signaling leads to S6K1-mediated
phosphorylation of Ser85 in GLI1, enhancing GLI1 transcriptional
activity by disrupting its interaction with the negative GLI regula-
tor SUFU [98]. Of note, the S6K1 phosphorylation site at Ser85 of
GLI1 is located in a D-site motif that serves as MAP  kinase binding
site required for phosphorylation and activation of GLI1 by JNK and
ERK [160] (Fig. 6). S6K1 phosphorylation may  therefore not only
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Fig. 6. Post-translational modiﬁcations regulate GLI transcriptional activity. Fine-tuning of GLI activity by phosphorylation/dephosphorylation and acetylation/deacetylation.
Left:  fully activated GLI transcription factor with multiple phosphorylated serine/threonine residues in the N-terminal region and the DNA binding domain. In addition, de-
acetylation promotes DNA binding afﬁnity and transcriptional activity, respectively. Several kinases (MAPK, S6K, aPKC) and deacetylases catalyze the activation of GLI, while
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nterfere with SUFU binding but also modify GLI phosphorylation
y MAP  kinases.
A cluster of non-consensus PKA phosphorylation sites (ncPKA)
n close proximity to the SUFU binding site has also been shown to
egulate GLI2/3 activation, though the GLI activating kinase respon-
ible for phosphorylating ncPKA sites has not been identiﬁed [161].
hether phosphorylation of ncPKA sites activates GLI2/3 by dis-
upting the SUFU-GLI complex or by a different mode also needs to
e addressed in future studies.
A number of distinct phosphorylation events in the N-terminal
egion of GLI control full GLIA. This suggests that the N-terminus of
LI proteins serves as integration domain for multiple signals from
istinct pathways such as PI3K/AKT, mTOR/S6K or FGF/MEK/ERK
ignaling [65,98,162]. In line with an integration function of the
-terminal region, deletion of the GLI1 N-terminus abolishes its
ctopic activation of FoxA2 (HNF3)  in the neural tube [30] and its
yperactivation in response to FGF treatment [162]. It follows that
his integration domain plays a major role in the ﬁne-tuning of GLI
ctivity in normal tissues and importantly, also in the irreversible
ctivation of GLI in cancer cells.
Besides phosphorylation, acetylation of GLI is another param-
ter in the complex regulation of GLI transcriptional activity.
cetylation of GLI2 at Lys757 by the histone acetyl transferase
300 is a critical negative regulatory modiﬁcation in HH signaling
157]. Interestingly, acetylated GLI2 displays signiﬁcantly reduced
ecruitment to chromatin and consequently only weak activa-
or potential [157]. As the acetylation site is C-terminal of the
NA binding domain it is unlikely that acetylation directly affects
NA binding afﬁnity. Rather, deacetylation may  favor the interac-
ion of GLI with chromatin bound proteins and therefore enhance
ts recruitment to target gene enhancers/promoters. Indeed, HH
ignaling promotes deacetylation of GLI1/2 via inducing class I his-
one deacetylases (HDAC), which has been identiﬁed as important
tep in the activation of GLI target gene expression [157,158].
In summary, the remarkable progress in our understanding of
LI modiﬁcations highlights context-dependent reversible post-
ranslational modiﬁcations as critical determinants of GLI activity.
ere, selected kinases (MAPK, S6K1 and aPKC) and deacetylases
HDAC) act as positive regulators, while acetylases (p300), PKA
161] and as yet unidentiﬁed phosphatases control the termination
f HH signaling via GLI inactivation (Fig. 6). In cancer a number of
hese components are deregulated, thus contributing to the onco-
enic load that regulate the GLI code.. Outlook
Whereas great progress has been made to understand how
he GLI proteins act (e.g., reviewed in [7,21,58,59,64,163]), much phosphorylation of the two amino acid residues C-terminal of the DNA binding
ng or stability [161]. ncPKA: non-consensus PKA phosphorylation sites involved in
remains to be understood. For example, it is not clear what are effec-
tive endogenous concentrations of GLI proteins, how they interact
with co-factors, how can they be modiﬁed in cells receiving simul-
taneous inputs, how their activity can be affected by and affect
epigenetic changes, how they are protected from cleavage or mod-
iﬁcation, or even how the pathway is effectively turned off when
required.
Documenting the full range of inputs and factors that can mod-
ulate their activities in multiple developmental, homeostatic and
disease contexts will require much effort but will certainly be a
good start. Such knowledge may allow us to begin to understand
the logic of signaling in development, in disease and hopefully also
in evolution. Thus, we  promote the idea that these analyses must
be carried out in all possible species and cell types in order to com-
pare and contrast mechanisms and outcomes in a quest to extract
essential signaling principles as well as speciﬁc solutions for each
system.
A more anthropocentric goal is to understand how the GLI code
is perverted in human disease, and speciﬁcally in cancer, through
pathway corruption and the oncogenic load. Such knowledge will
possibly lead us to design novel and more efﬁcient therapies against
multiple forms of deadly cancers, including those of the brain, intes-
tine, lung, skin, pancreas and other organs. Indeed, the involvement
of HH-GLI signaling in normal stem cell lineages and in cancer stem
cells [54] raises the possibility that novel molecular approaches to
block positive GLI function, reverting the GLI code, could be highly
beneﬁcial.
For example, the discovery of aPKC, PI3K/AKT, mTOR/S6K or EGF
signaling (see above) as part of the oncogenic load and, importantly,
as druggable GLI modulators has already pointed out possible ways
of how to design novel combination treatments with improved
therapeutic beneﬁt [64,65,90,98,164,165]. However, despite the
increasing number of studies of GLI regulation in health and dis-
ease, we are only beginning to realize the remarkable complexity of
context-dependent regulatory processes affecting the GLI code. The
identiﬁcation and in depth analysis of modiﬁers of the GLI code will
guide us to the development of better rational combination treat-
ments by synergistically targeting the core of the HH-GLI pathway
itself, and its modiﬁers. This will also open therapeutic oppor-
tunities to tackle the problem of relapse and drug resistance, as
exempliﬁed by the successful targeting of aPKC in SMOH inhibitor-
resistant basal cell carcinomas [156].
We are now entering an era where the GLI transcription factors
and their modulators are beginning to take center stage as drug
targets. Targeting transcription factors for cancer therapy has
long been considered not effective, but clearly the number of
recent examples such as those mentioned above along with the
identiﬁcation of small molecule GLI antagonists [166,167] provide
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mple proof-of-concept for the therapeutic relevance of such
n approach. Given the essential function of GLIs in normal and
alignant stem cells, the systematic identiﬁcation and functional
nalysis of GLI modulators, particularly of those amenable to small
olecule targeting, as well as studies addressing their context-
ependent activity will be an area of intense future research with
igniﬁcant impact on several medical areas such as cancer, tissue
egeneration and wound healing.
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